Tiotropium / Respimat One-Year Study

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

Key facts

Study ID

NCT00168844

Run by

Boehringer Ingelheim

People needed

983

Starts

2003-01-01

Last updated by the study team

2014-05-20

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Boehringer Ingelheim Investigational Site — Pismo Beach, California, United States
• Boehringer Ingelheim Investigational Site — San Diego, California, United States
• Boehringer Ingelheim Investigational Site — Fort Collins, Colorado, United States
• Boehringer Ingelheim Investigational Site — Minneapolis, Minnesota, United States
• Boehringer Ingelheim Investigational Site — Larchmont, New York, United States
• Boehringer Ingelheim Investigational Site — Raleigh, North Carolina, United States
• Boehringer Ingelheim Investigational Site — Chattanooga, Tennessee, United States
• Boehringer Ingelheim Investigational Site — Harker Heights, Texas, United States
• Boehringer Ingelheim Investigational Site — Houston, Texas, United States
• Boehringer Ingelheim Investigational Site — Fredericksburg, Virginia, United States
• Boehringer Ingelheim Investigational Site — Harrisonburg, Virginia, United States
• Boehringer Ingelheim Investigational Site — Toorak Gardens, South Australia, Australia
• Boehringer Ingelheim Investigational Site — Woodville, South Australia, Australia
• Boehringer Ingelheim Investigational Site — Clayton, Victoria, Australia
• Boehringer Ingelheim Investigational Site — Frankston, Victoria, Australia
• Boehringer Ingelheim Investigational Site — Perth, Western Australia, Australia
• Boehringer Ingelheim Investigational Site — Antwerp, Belgium
• Boehringer Ingelheim Investigational Site — Brussels, Belgium
• Boehringer Ingelheim Investigational Site — Genk, Belgium
• Boehringer Ingelheim Investigational Site — Ghent, Belgium
• Boehringer Ingelheim Investigational Site — Liège, Belgium
• Boehringer Ingelheim Investigational Site — Wavre, Belgium
• Boehringer Ingelheim Investigational Site — Edmonton, Alberta, Canada
• Boehringer Ingelheim Investigational Site — Halifax, Nova Scotia, Canada
• Boehringer Ingelheim Investigational Site — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.